地塞米松、甲氨蝶呤及环磷酰胺等联合治疗外周T细胞淋巴瘤的临床效果研究

Clinical Efficacy of Dexamethasone,Methotrexate Combined with Cyclophosphamide for Treatment of Patients with Peripheral T-cell Lymphoma

目的:探讨地塞米松,甲氨蝶呤及环磷酰胺等联合治疗外周T细胞淋巴瘤(PTCL)的临床效果。方法:选取2005年9月至2007年4月我院收治的PTCL患者21例作为对照组,并给予CHOP方案治疗;选取2007年8月至2009年9月我院收治的PTCL患者29例作为观察组,并给予Hyper-CVAD方案治疗,治疗后比较两组疗效。结果:对照组CR 6例,PR 4例,总有效率47.6%;观察组CR 15例,PR 7例,总有效率75.9%;观察组治疗总有效率显著性高于对照组。在治疗过程中观察组和对照组间患者心功能障碍,恶心呕吐等不良反应发生率无统计学差异。观察组患者平均PFS为26.106个月,显著性长于对照组的17.542个月。结论:地塞米松,甲氨蝶呤及环磷酰胺等联合治疗外周T细胞淋巴瘤的临床效果满意,建议在临床中应用。

Objective：This study was aimed to investigate the clinical efficacy of dexamethasone, methotrexate combined with cyclophosphamide for treatment of patients with peripheral T-cell lymphoma（PTCL）. Methods：Twenty -one patients with peripheral T-cell lymphoma were selected as control group, which were received CHOP; twenty - nine patients with peripheral T-cell lymphoma were selected as treatment group, which were received Hyper-CVAD. Clinical efficacy were observed after treatment. Results：In control group 6 patients achieved complete remission（ CR）, 4 patients achieved partial remission（PR）, the total response rate of control group was 47.6% ; in treatment group 15 patients achieved CR, 7 patients achieved PR, the total response rate of treatment group was 75.9%, and the total response rate of treatment group was significantly higher than that of control group. The incidence rates of cardiac dysfunction, peripheral neuropathy, anaemia and leucopenia between the two groups had no significant difference. The average progress free survival （PFS） of treatment group was 26.106 months, which was significantly higher than that of control group. Conclusion：The clinical efficacy of dexamethasone, methotrexate combined with cyclophosphamide for treatment of patients with peripheral T-cell lymphoma has been confirmed to be satisfactory and it may be used in clinic.